Alector, Inc. (NASDAQ:ALEC) Faces Downgrade Amid Drug Trial Setback

Font: Financial Modeling Prep  • Oct 22, 2025

• William Blair downgraded Alector, Inc. (NASDAQ:ALEC) from "Outperform" to "Market Perform" following a failed drug trial.
• The company's stock price has significantly declined, currently standing at $3.21, after the announcement of the trial's failure.
• Alector's market capitalization is approximately $324.9 million, with a trading volume of 1,393,229 shares on the NASDAQ.

Alector, Inc. (NASDAQ:ALEC) is a biotechnology company focused on developing therapies for neurodegenerative diseases. The company aims to harness the power of the immune system to combat these conditions. Alector faces competition from other biotech firms working on similar treatments, but its unique approach sets it apart in the industry.

On October 22, 2025, William Blair downgraded Alector's stock from "Outperform" to "Market Perform." This change came as ALEC's stock price stood at $3.21. The downgrade reflects concerns about the company's recent challenges, particularly the failure of its experimental drug in a late-stage trial.

Alector's shares have seen a significant decline following the announcement that its drug did not slow the progression of a rare form of dementia. This setback led the company to terminate the study and reduce its workforce by nearly half. The stock price, currently at $3.21, has decreased by 3.02%, with a change of $0.10.

The stock has fluctuated between $3.09 and $3.27 today, highlighting the market's reaction to recent developments. Over the past year, ALEC has experienced a high of $6.14 and a low of $0.87. The company's market capitalization is approximately $324.9 million, indicating its current valuation in the market.

Alector's trading volume on the NASDAQ is 1,393,229 shares, reflecting investor interest and activity. Despite the recent challenges, the company remains focused on its mission to develop innovative therapies for neurodegenerative diseases.